CASI CLINICI

Triazolam, obesity and non cardiac pulmonary edema

Triazolam, obesità ed edema polmonare non cardiogeno

Fabio Di Stefano *, Salvatore Nicolai, Filippo Salvati

Dipartimento di Medicina Interna, Presidio Ospedaliero G. Bernabeo, Azienda USL 2 Lanciano-Vasto-Chieti

Received 22 September 2011; accepted 21 February 2012
Available online 4 April 2012

KEYWORDS
Non cardiac pulmonary edema;
Adverse drug reaction;
Triazolam;
Obesity.

Summary

Introduction: Triazolam belongs to the group of benzodiazepines and may have side effects on the respiratory system which include not only respiratory depression, but also transient benign non cardiac pulmonary edema.

Case report: A 52 year old obese woman developed pulmonary edema after she was taking triazolam for almost two weeks without any other medications. All possible cardiogenic and non cardiogenic causes were excluded. The condition was severe enough to require non invasive ventilation.

Discussion: This case differs from the other report of triazolam associated non cardiac pulmonary edema for its severity requiring non invasive ventilation. The pathogenetic mechanism is unknown. Despite the lack of objective evidence to explain pulmonary venous hypertensive changes in our case, we want to advice that triazolam should be used with caution in obese patients, as obesity might aggravate this described drug adverse reaction.

© 2012 Elsevier Srl. All rights reserved.

Introduction

Triazolam belongs to the group of benzodiazepines and may have side effects on the respiratory system which include not only respiratory depression, but also transient benign non cardiac pulmonary edema [1]. This form of non cardiac pulmonary edema is not life threatening (PaO₂/FiO₂ is always superior to 400), is usually auto-resolving within few hours and may be associated to many drugs (Table 1).

We report a severe form of triazolam associated non cardiac pulmonary edema in an obese patient requiring non invasive ventilation.

Case report

A 52 year old woman (Body Mass Index 34) presented with severe dyspnea progressive increasing in few days. On examination heart rate was 120 bpm, blood pressure 150/80 mmHg,
Table 1  Causative drugs of transient benign non cardiac pulmonary edema according to references reported by Pneumotox On Line (www.pneumotox.com).

| Drug                  | Acetazolamide | Gemcitabine | Propofol |
|-----------------------|---------------|-------------|----------|
| Acetylsalicylic acid  | Ibuprofen     | Hydrochlorothiazide | Propranolol |
| Adrenaline            | Dexamethasone | Prostaglandin | Prostacilin |
| Albumin               | Dextran       | Immunoglobulins (IV) | Protamine |
| Amitriptyline         | Deferoxamine  | Insulin     | Pyrimethamine-sulfadoxine |
| Amphotericin B        | Interleukin 2 | Methotrexate | Retinoic acid |
| Basiliiximab          | Ketamine      | Methadone   | Ritodrine |
| Buprenorphine         | Lidocaine     | Methotrexate | Rituximab |
| Carbamazepine         | Minocycline   | Medroxyprogesterone | Rosiglitazone |
| Chlorpromazine        | Morphine (agonists/antagonists) | Metamizole | Salbutamol |
| Cloniphene            | Methadone     | Methadone   | Sulfasalazine |
| Codeine               | Methotrexate  | Sulfonamides| |
| Colchicine            | Minocycline   | Nitroglycerin| Thiazolidinediones |
| Cotrimoxazole         | Morphine (agonists/antagonists) | Nitroglycerin | Troglitazone |
| Cyclophosphamide      | Nicardipine   | Oxycodone   | AbMo antitumor necrosis factor-alpha |
| Cyclosporin           | Nitroglycerin | Paclitaxel  | Vasopressin |
| Deferoxamine          | Oxycodone     | Paclitaxel  | Vinorelbine |
| Dexamethasone         | Paclitaxel    | Phenylbutazone | |
| Dextran               | Paclitaxel    | Phenylephrine | |
| Diltiazem             | Paclitaxel    | Phenylephrine | |
| Erythromycin          | Pioglitazone  | Pioglitazone | |

respiratory rate 40 breaths/min and temperature 36.7 °C. Auscultation of heart was normal, while chest auscultation revealed inspiratory crackles bilaterally. Peripheral edema and jugular venous distension were not present. The electrocardiogram showed only sinus tachycardia. The chest radiograph showed diffuse asymmetric bilateral infiltrates with normal cardiac size and vascular pedicle width; the distribution of blood flow in the lung was not inverted and Kerley lines were not seen. Transthoracic echocardiogram showed normal cardiac dimensions (luminal diameters and septal thickness), cardiac output as well as ejection fraction, valve areas and function; systolic pulmonary artery pressure of 41 mmHg, considered with the limitations of the method at the upper limit of normality [2]. Abdominal ultrasound was normal and there were no pleural effusions on chest echography.

Physical findings, chest radiograph and transthoracic echocardiogram were indicative of non cardiac pulmonary edema.

Initially in the emergency room she was given by nursing staff high flow oxygen by a Ventimask with a FiO2 of 40% to maintain arterial oxygen saturation of hemoglobin (SaO2) around 90-92%. Subsequently she was given 4 L/min oxygen by a Ventimask with a FiO2 of 28% and arterial blood gas analysis revealed PaO2 64 mmHg, PaCO2 59 mmHg, HCO3⁻ 33 mmol/L, pH 7.37.

The PaO2/FiO2 ratio of 229 was consistent with a severe hypoxemia, but not yet an acute respiratory distress syndrome (ARDS) defined by a PaO2/FiO2 ratio of less than 200.

Laboratory investigation showed: erythrocyte sedimentation rate 10 mm/h; WBC 6,300 x 10⁹/µL with 64% neutrophils and 28% lymphocytes; RBC 4.76 x 10⁹/µL; HGB 14 g/dL; HCT 45.8% and PLT 205 x 10⁹/µL; BUN 19 mg/dL and serum creatinine 0.65 mg/dL; blood glucose 113 mg/dL; D-dimer 54 ng/mL; serum electrolytes and urine analysis normal.

Many possible causes of non cardiac pulmonary edema (intravenous fluid overload; neurogenic causes as seizures, head trauma and electrocution; inhalation of toxic gases; pulmonary contusion; aspiration of gastric fluid or other liquids; blood transfusions; severe infections; illicit drug use) were excluded on the basis of history, physical examination, instrumental and laboratory investigations. Pulmonary embolism, which rarely may be associated with non cardiac pulmonary edema, was excluded by the absence of any ECG and ultrasound signs of right heart acute overload and by serial measurements of D-dimer always normal. From history resulted that she was taking triazolam for almost two weeks without any other medications. Therefore we interpreted the pulmonary edema as an adverse side effect of this drug.

The patient had received intravenous furosemide (40 mg) and continuous intravenous infusion of nitrates (5 μg/min) in the emergency room. After the diagnosis of iatrogenic non cardiac pulmonary edema, she was empirically treated with high doses of intravenous steroids (prednisolone 1mg/kg body weight), but the focus was on maintaining adequate oxygenation with non invasive ventilation. We used a bilevel assisted spontaneous breathing pressure support non invasive ventilation with an inspiratory positive airway pressure
(IPAP) of 20 cm H₂O and an expiratory positive airway pressure (EPAP) of 7 cm H₂O, back up respiratory rate of 15 breaths/min and back up inspiratory/expiratory time ratio of 1:3. The patient oxygenation increased promptly and non invasive ventilation was withdrawn after almost 12 hours excluding the short periods off the ventilator. She continued to improve and was then discharged on the eighth hospital day in good and stable condition with the following arterial blood gases on air: PaO₂ 70.1 mmHg; PaCO₂ 47 mmHg; HCO₃⁻ 29 mmol/L; pH 7.39.

**Discussion**

The pathogenetic mechanism of non cardiac pulmonary edema is usually due to direct toxic stimulus, as in the case of aspiration of gastric contents, inhalation of toxic substances or closed chest trauma, or to systemic insults (infections and sepsis, trauma, repeated blood transfusions, pancreatitis, etc.) which cause the release of several inflammatory cells and mediators [3].

We report a case of non cardiac pulmonary edema associated with the use of triazolam. The pathogenetic mechanism of triazolam as well as many other drugs associated non cardiac pulmonary edema (Table 1) is unknown. This case differs from the other report [1] for its severity requiring non invasive ventilation. Pulmonary venous hypertension may be frequent in obese individuals as it has been found by an autoptic study of Haque et al. [4], but in our case the absence of echocardiographic signs of right ventricular overload and of left ventricular dysfunction seems to not justify pulmonary venous hypertensive changes aggravating the condition.

In conclusion, despite the lack of objective evidence to explain the severity of this drug associated non cardiac pulmonary edema, previously described transient and benign [1], the take-home message from this report is that triazolam should be used with caution in obese patients, as obesity might aggravate this described drug adverse reaction and may have already determined compromised ventilatory performances in affected subjects.

**Conflict of interest statement**

The authors have no conflict of interest to disclose.

**References**

[1] Chan TH, Ho SS, Li PKT. Noncardiogenic pulmonary edema associated with triazolam. J Toxicol Clin Toxicol 1995;33(2):185–7.
[2] McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104(23):2797–802.
[3] Villar J, Blanco J, Kacmarek RM. Acute respiratory distress syndrome definition: do we need a change? Curr Opin Crit Care 2011;17(1):13–7.
[4] Haque AK, Gadre S, Taylor J, Haque SA, Freeman D, Duarte A. Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects. Arch Pathol Lab Med 2008;132(9):1397–404.